{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:44:43Z","timestamp":1793385883802,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T00:00:00Z","timestamp":1612051200000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ijrobp.2019.10.043","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T11:39:21Z","timestamp":1573126761000},"page":"589-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Solitary Plasmacytoma Treated by Lenalidomide-Dexamethasone in Combination with Radiation Therapy: Clinical Outcomes"],"prefix":"10.1016","volume":"106","author":[{"given":"Fabien","family":"Mignot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Schernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Ars\u00e8ne-Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Vignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Bouscary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlia","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2019.10.043_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2141.2008.07421.x","article-title":"Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: Incidence and survival in the United States, 1992-2004","volume":"144","author":"Dores","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijrobp.2005.06.039","article-title":"Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients","volume":"64","author":"Ozsahin","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12885-016-3015-5","article-title":"Solitary plasmacytoma: Population-based analysis of survival trends and effect of various treatment modalities in the USA","volume":"17","author":"Thumallapally","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib5","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1002\/cncr.26031","article-title":"Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy","volume":"117","author":"Reed","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ijrobp.2010.11.037","article-title":"Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy","volume":"82","author":"Sasaki","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0360-3016(00)01572-8","article-title":"Solitary plasmacytoma treated with radiotherapy: Impact of tumor size on outcome","volume":"50","author":"Tsang","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1186\/s12885-016-2824-x","article-title":"Establishment of an innovative staging system for extramedullary plasmacytoma","volume":"16","author":"Zhu","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2407-6-118","article-title":"Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study","volume":"6","author":"Knobel","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib10","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation therapy for solitary plasmacytoma and multiple myeloma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/(SICI)1099-1069(199609)14:3<111::AID-HON575>3.0.CO;2-G","article-title":"Improved outcome in solitary bone plasmacytomata with combined therapy","volume":"14","author":"Avil\u00e9s","year":"1996","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib12","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/blood-2014-04-566521","article-title":"Outcome prediction in plasmacytoma of bone: A risk model utilizing bone marrow flow cytometry and light-chain analysis","volume":"124","author":"Hill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.23745","article-title":"Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients","volume":"89","author":"Katodritou","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.14291","article-title":"Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands","volume":"175","author":"de Waal","year":"2016","journal-title":"Br J Hematol"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib15","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1080\/10428194.2017.1393667","article-title":"Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy","volume":"159","author":"Le Ray","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4329\/wjr.v5.i6.248","article-title":"Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study","volume":"5","author":"Wiazzane","year":"2013","journal-title":"World J Radiol"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4514.4514","article-title":"Adjuvant chemotherapy in the treatment of solitary bone plasmacytoma","volume":"128","author":"Mheidly","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib18","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European expert panel","volume":"11","author":"Caers","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0360-3016(89)90008-4","article-title":"Solitary plasmacytoma of bone: Mayo Clinic experience","volume":"16","author":"Frassica","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib21","first-page":"1659","article-title":"Prognostic factors associated with solitary plasmacytoma","volume":"6","author":"Guo","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bjh.13870","article-title":"Clinical features and prognostic factors in solitary plasmacytoma","volume":"172","author":"Finsinger","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib23","doi-asserted-by":"crossref","first-page":"e0219857","DOI":"10.1371\/journal.pone.0219857","article-title":"Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era","volume":"14","author":"Sharpley","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.meddos.2010.12.009","article-title":"The role of helical tomotherapy in the treatment of bone plasmacytoma","volume":"37","author":"Chargari","year":"2012","journal-title":"Med Dosim"},{"key":"10.1016\/j.ijrobp.2019.10.043_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-0609.2009.01251.x","article-title":"Solitary plasmocytoma: Improvement in critical organs sparing by means of helical tomotherapy","volume":"83","author":"Chargari","year":"2009","journal-title":"Eur J Haematol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619339677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619339677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:46:05Z","timestamp":1759743965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301619339677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0360301619339677"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.10.043","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Solitary Plasmacytoma Treated by Lenalidomide-Dexamethasone in Combination with Radiation Therapy: Clinical Outcomes","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}